GlassScriptPhysician profile
Andrew M Silvera
NPI 1356927982
$2,587.41
in general payments reported to CMS, 2019-2025
16 companies · $1,034 in 2025
The $1,034 reported for 2025 was more than what 81% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $120 · 2023: $894 · 2024: $539 · 2025: $1,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,429 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,429.33 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $663.34 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $561.76 | 2023-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Abbvie INC. | $305.35 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $231.80 | 2023-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $186.20 | 2023-2025 | Austedo Xr, Uzedy, Austedo |
| Idorsia Pharmaceuticals US INC | $134.42 | 2023 | Quviviq |
| Neurocrine Biosciences, INC. | $122.40 | 2024-2025 | Ingrezza |
| Indivior INC. | $65.73 | 2023 | Perseris |
| Tris Pharma INC | $61.47 | 2023-2024 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $57.90 | 2024-2025 | Auvelity |
| Lundbeck LLC | $55.34 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $42.31 | 2023 | Trintellix |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $37.64 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.86 | 2023-2024 | Caplyta |
| Luye Pharma (USA) LTD. | $15.43 | 2025 | Erzofri Extended-Release |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $14.46 | 2025 | Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Silvera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.